Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation ir ādas stāvoklis, kam raksturīgs palielināts pigments ādā pēc ādas iekaisuma. Postinflammatory hyperpigmentation var izraisīt ilgstoša saules iedarbība, iekaisums vai citi ādas bojājumi, tostarp tie, kas saistīti ar pūtītēm. Cilvēki ar tumšāku ādas toni parasti ir vairāk pakļauti hiperpigmentācijai ar pārmērīgu saules iedarbību.
☆ 2022. gada Stiftung Warentest rezultātos no Vācijas patērētāju apmierinātība ar ModelDerm bija tikai nedaudz zemāka nekā ar maksas telemedicīnas konsultācijām.
References
Postinflammatory hyperpigmentation (PIH) ir bieža ādas problēma, kas rodas pēc ādas iekaisuma vai traumas. Tas mēdz ilgt ilgu laiku un ir sliktāks cilvēkiem ar tumšāku ādas toni (Fitzpatrick skin types III–VI) . Lai gan tas bieži vien uzlabojas pats par sevi, tas var aizņemt kādu laiku, tāpēc ārstēšana bieži vien ir nepieciešama ilgu laiku. Vislabāk darbojas dažādu ārstēšanas metožu apvienošana.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation ir bieži sastopamas ādas iekaisuma sekas. Tam ir tendence smagāk un biežāk ietekmēt cilvēkus ar tumšāku ādu. Pētījumi liecina, ka tādas problēmas kā postinflammatory hyperpigmentation ir viens no galvenajiem iemesliem, kāpēc cilvēki ar tumšāku ādas toni meklē dermatoloģisku aprūpi. Agrīna ārstēšana ir ļoti svarīga, lai atrisinātu postinflammatory hyperpigmentation , un parasti tā sākas ar sākotnējā iekaisuma stāvokļa pārvaldību. Pirmā ārstēšanas līnija parasti ietver lokālu līdzekļu izmantošanu, kas padara ādu gaišāku, kopā ar sauļošanās līdzekli aizsardzībai. Šie līdzekļi, piemēram, hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , var efektīvi samazināt pārmērīgu pigmentāciju. Turklāt retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy tiek izmantoti arī kā depigmentācijas līdzekļi, un parādās jaunas ārstēšanas metodes. Lai gan lokāla ārstēšana parasti ir efektīva virsmas līmeņa hiperpigmentācijas gadījumā, procedūras (laser, chemical peel) var būt nepieciešamas spītīgos gadījumos. Ir svarīgi ievērot piesardzību ar šīm procedūrām, lai izvairītos no kairinājuma un postinflammatory hyperpigmentation pasliktināšanās.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
